Riskpilot← Back to searchSign inGet full accessGOKSTAD PHARMINVEST AS
ASActiveOrg 994802445Solbergveien 62, 3232 SandefjordEconomic activity was not specified by tax authority · NACE 0000Est. 20090 employees
Revenue 2022
NOK 0
EBITDA margin
—
+42% vs 2021
Equity ratio
18.2%
Financial strength
Net profit 2022
NOK -9K
+42% vs 2021
| Revenue | NOK 0 | — |
| EBITDA | NOK -9K | +42% |
| Net profit | NOK -9K | +42% |
| Total assets | NOK 11K | -59% |
| Equity | NOK 2K | -82% |
| Employees | 0 | — |
Legal name
GOKSTAD PHARMINVEST AS
Org number
994802445
Legal form
Aksjeselskap
NACE code
0000 · Economic activity was not specified by tax authority
Founded
24. november 2009
Share capital
NOK 10 000 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Investering og deltagelse i andre selskap og virksomheter, og alt hva dermed står i forbindelse.
Address
Solbergveien 62, 3232 Sandefjord
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −12 | −7 | −6 | −16 | −9 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −12 | −7 | −6 | −16 | −9 |
| Net financials | −84 | 0 | 0 | 0 | 0 |
| Profit before tax | −95 | −7 | −6 | −16 | −9 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −95 | −7 | −6 | −16 | −9 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 41 | 34 | 28 | 28 | 11 |
| Equity | 41 | 34 | 28 | 11 | 2 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | 16 | 9 |
| Total debt | 0 | 0 | 0 | 16 | 9 |
EBITDA margin
-931700.0%
This company
15.8%
Market median
-5896935% vs market
20182022
Equity ratio
18.2%
This company
38.2%
Market median
-52% vs market
20182022
Return on equity
-451.0%
This company
18.4%
Market median
-2551% vs market
20182022
Net profit margin
-931700.0%
This company
8.1%
Market median
-11502569% vs market
20182022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182022
Debt / equity
4.51×
This company
0.62×
Market median
-627% vs market
20182022
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2021 | |
| Board of Directors | 2021 | |
| Former (1) | ||
| Chairman | 2016 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 17.72% | 17.72% | 2022 | |
| Individual | 13.89% | 13.89% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of GOKSTAD PHARMINVEST AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Marianne Wikstøl Andersen | Chairman | 0 companies |
| Katarzyna Agata Gripsrud | Chairman | 0 companies |
| Tove Ereen Haugene Rønnestad | Board of Directors | 0 companies |